Dual-function toxin that inhibits both serine proteases and voltage-gated potassium channels (PubMed:26404319, PubMed:33158163). Has potent activity on both trypsin (Ki=28 nM) and chymotrypsin (Kd=1.8 nM) (PubMed:26404319). Shows inhibitory activity against 4 of the 7 potassium channels tested (rKv1.1/KCNA1; IC(50)=142.6 nM, hKv1.3/KCNA3; IC(50)=40.7 nM, rKv1.6/KCNA6; IC(50)=154.9 nM and drosophila Shaker; IC(50)=433.1 nM) (PubMed:33158163). Has an anti-inflammatory effect in LPS-activated macrophages in vitro, specifically reducing release of TNF and IL6 but not nitric oxide and reducing expression of IL1B precursor (PubMed:26404319). In contrast to some paralogs, this protein decreases reactive oxygen species (ROS) level in the oxidative stress agent 6-hydroxydopamine (6-OHDA)-induced neurotoxicity model, but does not show cytoprotective activity on neuroblastoma cells (PubMed:33802055). This protein also shows a weak free-radical scavenging activity (PubMed:33802055). In vivo, when tested in a mice model of acute local inflammation, it reduces paw edema during 24 hours. In addition, it also reduces the synthesis of TNF in this model (PubMed:33158163). Contains 3 disulfide bonds. Does not bind to and, hence, probably does not inhibit serine proteases plasmin, kallikrein and thrombin (PubMed:26404319). Has no or weak activity on hKv1.2/KCNA2 (IC(50)=52 uM), rKv1.4/KCNA4 and rKv1.5/KCNA5 (PubMed:33158163). Belongs to the venom Kunitz-type family. Sea anemone type 2 potassium channel toxin subfamily.